775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study

Authors :: Stephen B. Hanauer
Oksana Shchukina
Matthieu Allez
Edward V. Loftus
Long-Long Gao
Andrew Greenspan
Remo Panaccione
Christopher Gasink
James D. Lewis
Silvio Danese
Bruce E. Sands
Emese Mihály
Timothy Hoops
J Izanec
Vipul Jairath
Peter M. Irving
Tanja Kuehbacher
William J. Sandborn
Ellen Scherl
Source :: Gastroenterology. 161:e30-e31
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Moderate to severe
medicine.medical_specialty
Crohn's disease
Hepatology
business.industry
Gastroenterology
medicine.disease
Maintenance therapy
Internal medicine
Ustekinumab
medicine
Adalimumab
business
medicine.drug

Full Text Access

Tools